EVMN Stock: Stock Price, Analysis & Insights
Get live evmn stock price $20.23, comprehensive stock analysis, charts, news, and expert forecast. Real-time evmn stock data and investment insights.
Loading chart...
Company Overview
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Company Information
- CEO
- Luis C. Pena
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 45
Contact Information
- Website
- https://www.evommune.com
- Address
- 1841 Page Mill Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.00) may provide portfolio stability
Business Model & Strategy
null operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Luis C. Pena, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
null competes in the Biotechnology within the broader Healthcare. With 264.2 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, null provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating null should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for null shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for null
- ⚠Investors should consider how null fits within their overall portfolio allocation
Market Cap
264.21M
Beta
0.00
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 264.21M market capitalization
- Trading Volume: 2.48M shares traded today
- Price Range: 52-week range of $16.85 - $20.65
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for
(EVMN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 264.21M, the company represents a significant player in its market. The stock is currently trading at $20.23 with a positivedaily change of 26.44%.
The company's 45 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 0.00, beta of 0.00, and 52-week price range from $16.85 to $20.65when evaluating investment opportunities.
Why Invest in ?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Luis C. Pena
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.